Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
TRAEMOS
T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
- NCT03784599 ↗
- Terminated
- The Netherlands Cancer Institute
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on TRAEMOS (trastuzumab emtansine plus osimertinib in EGFR mutation-positive NSCLC with HER2 bypass track resistance) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TRAEMOS so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Trastuzumab-emtansine and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Trastuzumab emtansine; Osimertinib
- Arms
- Trastuzumab-emtansine and osimertinib · Experimental
- Enrollment
- 28
- Primary outcomes
- Safety (intensity and incidence of adverse events)
- Objective response rate according to RECIST v1.1 after 3 months of treatment
- Sponsor
- The Netherlands Cancer Institute with AstraZeneca, Roche Pharma AG
- Start
- Dec 18, 2018
- Primary completion
- May 17, 2021
- Results posted
- No
- Registry record
- NCT03784599 · updated Nov 10, 2022